AVTX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 23, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Avalo Therapeutics Enters into $200 Million At-The-Market Sales Agreement with Jefferies and Terminates Prior Sales Agreement with TD Cowen

Nov 5, 2026

8-K

Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

Nov 5, 2026

8-K

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Pipeline Updates

Aug 6, 2026

8-K

Avalo Therapeutics, Inc. Appoints Ron Philip to Board of Directors

Jun 23, 2026

8-K

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

Jun 16, 2026

8-K

Avalo Therapeutics Announces Preferred Stock Exchange and Executive Employment Agreement Amendments

Jun 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* November 2026 ATM | Offering amount: $200,000,000 | Bank: Jefferies LLC

Nov 5, 2026

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jul 28, 2026

424B5

REGISTERED OFFERING

May 6, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Leerink Partners, TD Cowen, BofA Securities

May 5, 2026

424B5

June ATM | Offering amount: $75,000,000 | Float: 10,671,868

Jun 5, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 3,432,523 | Warrants amount: 11,967,526 | Warrants exercise price: $5.80

Aug 5, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

November 2026 SHELF

Nov 5, 2026

S-3

SHARE RESALE REGISTRATION

Jul 17, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 23, 2026

S-3

January 2026 SHELF

Jan 8, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 6, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 12, 2025

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 6, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

SCHEDULE 13G

Trails Edge Capital Partners, LP (Filed by)

Oct 29, 2026

Jain Rita (Reporting)

Oct 2, 2026

Lind Kevin Robert (Reporting)

Oct 2, 2026

Philip Ron M (Reporting)

Oct 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 29, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 21, 2026

CORRESP

Form CORRESP - Correspondence

Jan 15, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jan 14, 2026

LETTER

Form UPLOAD - SEC-generated letter

Aug 6, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 6, 2024

Avalo Therapeutics, Inc. AVTX · SEC Filings